The Long View on Drug Shortages
This article was originally published in RPM Report
Executive Summary
Media headlines out of a Capitol Hill briefing on oncology drug approvals trumpeted new data showing that FDA is faster in approving new cancer treatments than the European Medicines Agency. The data will certainly surprise those who fault FDA for being too slow. But for actual legislative changes that may affect the oncology market, all the action is at the other end of the life-cycle, where the drug shortage problem is getting the most attention.